Day: October 31, 2022

On May 20, 1987, Hamaguchi, Shigeki; Katayama, Kazuhiko; Ohashi, Takehisa; Watanabe, Kiyoshi published a patent.Computed Properties of 97859-49-9 The title of the patent was Optically active 5-[(sulfonyloxy)methyl]-2-oxazolidinone derivatives as intermediates for drugs. And the patent contained the following:

The title compounds (I; R = SO2R1 where R1 = aryl), useful as intermediates for drugs, e.g., β-blockers, were prepared in good yield and with high optical purity by reaction of optically active crude I (R = H), which was prepared via stereospecific hydrolysis of I (R = COR2 where R2 = C7 or C8 alkyl) by a lipase from Pseudomonas aeruginosa with R1SO2X (X = halo) in the presence of a base in an inert solvent. p-MeC6H4SO2Cl (20 g) was added to a mixture of 14.6 g crude (S)-I (R = H) (80% purity) and 11 g Et3N in CH2Cl2 and the mixture was allowed to react at room temperature for 6 h to give 75% crystalline (S)-I (R = SO2C6H4Me-p). The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Computed Properties of 97859-49-9

The Article related to lipase asym hydrolysis hexanoyloxymethyloxazolidinone, chiral sulfonyloxymethyloxazolidinone preparation intermediate beta blocker, oxazolidinone preparation intermediate drug and other aspects.Computed Properties of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On August 31, 2006, Hattori, Kazuo; Niizuma, Satoshi; Masubuchi, Miyako; Koyama, Kohei; Kondoh, Osamu; Tsukaguchi, Toshiyuki; Okada, Takehiro published a patent.Product Details of 97859-49-9 The title of the patent was Preparation of 1-(2H)-isoquinolone derivatives as antitumor agents. And the patent contained the following:

The title compounds represented by the formula (I), prodrugs thereof, or pharmaceutically acceptable salts of either of them [X = each optionally substituted aryl or heteroaryl; ring Cy = optionally substituted 4-7 membered single heterocyclic ring or 8-10 membered fused heterocyclic ring; Z = O, S, Ra; Ra= H, C1-8 alkyl, aryl-C1-6 alkyl, aryl, heteroaryl]. These compounds are useful for effectively treating and preventing proliferative diseases such as cancers, in particular solid tumors. Thus, ring-opening amination of (R)-glycidol with 7-amino-3-(2-trifluoromethylphenyl)-2H-isoquinolin-1-one in ethanol under refluxing for 3 days gave 63% 7-((R)-2,3-dihydroxypropylamino)-3-(2-trifluoromethylphenyl)-2H-isoquinolin-1-one which underwent cyclocondensation with di-Et carbonate in the presence of NaOMe in methanol at 105° for 13 h to give 78% 7-((S)-5-Hydroxymethyl-2-oxooxazolidin-3-yl)-3-(2-trifluoromethylphenyl)-2H-isoquinolin-1-one. The representative compounds I showed IC50 of 0.021-0.96 against the proliferation of human colon cancer HCT116 cells. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Product Details of 97859-49-9

The Article related to isoquinolone preparation antitumor, proliferative disease cancer solid tumor treatment prevention isoquinolone preparation, oxooxazolidinylphenylisoquinolinone preparation antitumor and other aspects.Product Details of 97859-49-9

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On March 14, 2002, Madar, David J.; Pireh, Daisy; Kopecka, Hana; Djuric, Steven W.; Wiedeman, Paul E. published a patent.Quality Control of (R)-5-(Hydroxymethyl)oxazolidin-2-one The title of the patent was Preparation of oxazolidinones as antibacterial agents. And the patent contained the following:

The preparation of oxazolidinones [I; wherein A = Ph, five- or six-membered ring containing 1-3 atoms selected from N, O, and S; B = heterocycle; X = O, S, S(O), SO2, and NR5 (where R5 = H, alkyl, arylalkyl); R1, R2, independently = H, alkoxy, alkyl, amino, cycloalkyl, halo, etc.; R3 = H, alkoxy, alkyl, amino aryl, etc.; R4 = alkanoyl, alkoxycarbonyl, amido, aryl, etc.] is described. Thus, a multistep synthesis of N-[[(5S)-3-[3-fluoro-4-[(E)-[2-oxo-1,2-dihydro-3H-pyrrolo(2,3-b)pyridin-3-ylidene]methyl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide is given. The prepared compounds are useful as, inter alia, antibacterial agents, inhibiting the growth of bacteria with min. inhibitory concentrations in a range of about 2 μg/mL to about 8 μg/mL. The experimental process involved the reaction of (R)-5-(Hydroxymethyl)oxazolidin-2-one(cas: 97859-49-9).Quality Control of (R)-5-(Hydroxymethyl)oxazolidin-2-one

The Article related to oxazolidinone preparation antibacterial, psoriasis treatment preparation oxazolidinone, antiarthritic preparation oxazolidinone, chemotherapy toxicity treatment preparation oxazolidinone and other aspects.Quality Control of (R)-5-(Hydroxymethyl)oxazolidin-2-one

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

Campbell, Craig D.; Concellon, Carmen; Smith, Andrew D. published an article in 2011, the title of the article was Catalytic enantioselective Steglich rearrangements using chiral N-heterocyclic carbenes.Product Details of 168297-86-7 And the article contains the following content:

The evaluation of a range of enantiomerically pure NHCs, prepared in situ from imidazolinium or triazolium salt precatalysts, to promote the catalytic enantioselective Steglich rearrangement of oxazolyl carbonates I (R = Bn, Me, Et, CH2CHMe2, CH2C6H4OBn-4; R1 = Ph, Me, CMe2CCl3) to their C-carboxyazlactones II is reported. Modest levels of enantioselectivity (up to 66% ee) are observed using oxazolidinone derived NHCs. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Product Details of 168297-86-7

The Article related to carboxyazlactone enantioselective preparation reaction mechanism, oxazolyl carbonate steglich rearrangement chiral n heterocyclic carbene catalyst, imidazolinium salt triazolium salt precatalyst and other aspects.Product Details of 168297-86-7

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On September 7, 2007, Beddow, James E.; Davies, Stephen G.; Ling, Kenneth B.; Roberts, Paul M.; Russell, Angela J.; Smith, Andrew D.; Thomson, James E. published an article.SDS of cas: 168297-86-7 The title of the article was Asymmetric synthesis of β2-amino acids: 2-substituted-3-aminopropanoic acids from N-acryloyl SuperQuat derivatives. And the article contained the following:

Conjugate addition of lithium dibenzylamide to the SuperQuat derivative (S)-3-acryloyl-4-isopropyl-5,5-dimethyloxazolidin-2-one (derived from L-valine) and alkylation of the resultant lithium β-amino enolate provide, after deprotection, a range of (S)-2-alkyl-3-aminopropanoic acids in good yields and high enantiomeric excesses. Alternatively, conjugate addition of a range of secondary lithium amides to (S)-3-(2-alkylacryloyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one SuperQuat derivatives, diastereoselective protonation with 2-pyridone, and subsequent deprotection furnish a range of (R)-2-alkyl- and (R)-2-aryl-3-aminopropanoic acids in good yields and high enantiomeric excesses. Addnl., the boron-mediated aldol reaction of β-amino N-acyloxazolidinones is a highly diastereoselective method for the synthesis of a range of β-amino-β’-hydroxy N-acyloxazolidinones. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).SDS of cas: 168297-86-7

The Article related to alkylaminopropanoic acid preparation conjugate addition alkylation, superquat derivative conjugate addition alkylation, oxazolidinone amino hydroxy acyl preparation, asym synthesis beta amino acid and other aspects.SDS of cas: 168297-86-7

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

Montagnat, Oliver D.; Lessene, Guillaume; Hughes, Andrew B. published an article in 2010, the title of the article was Synthesis of Azide-alkyne Fragments for ‘Click’ Chemical Applications. Formation of Chiral 1,4-Disubstituted-(β-alkyl)-γ-1,2,3-triazole Scaffolds from Orthogonally Protected Chiral β-Alkyl-trialkylsilyl-γ-pentynyl Azides and Chiral β-Alkyl-γ-pentynyl-alcohols.Name: (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one And the article contains the following content:

A library of chiral γ-pentynyl alcs., I, and γ-pentynyl azides, e.g. II, was made using the SuperQuat chiral oxazolidin-2-one auxiliary. Coupling of the free alkynes with the azides by Huisgen 1,3-dipolar cycloaddition provided chiral oligomeric 1,4-disubstituted-1,2,3-triazoles, e.g. III, as possible peptidomimetic compounds The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Name: (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one

The Article related to asym alkylation chiral auxiliary pentynyl alc azide preparation, huisgen dipolar cycloaddition chiral pentynyl alc azide reactant, click chem disubstituted triazole preparation pentynyl alc azide reactant and other aspects.Name: (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On December 1, 2019, Cao, Hengyi; Zhu, Guangya; Sun, Lin; Chen, Ge; Ma, Xinxin; Luo, Xiao; Zhu, Jidong published an article.Formula: C8H15NO2 The title of the article was Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration. And the article contained the following:

Isocitrate dehydrogenase 1 (IDH1), which catalyzes the conversion of isocitrate to α-ketoglutarate, is one of key enzymes in the tricarboxylic acid cycle (TCA). Hotspot mutation at Arg132 in IDH1 that alters the function of IDH1 by further converting the α-ketoglutarate(α-KG) to 2-hydroxyglutarate (2-HG) have been identified in a variety of cancers. Because the IDH1 mutations occur in a significant portion of gliomas and glioblastomas, it is important that IDH1 inhibitors have to be brain penetrant to treat IDH1-mutant brain tumors. Here we report the efforts to design and synthesize a novel serial of mutant IDH1 inhibitors with improved activity and the blood-brain barrier (BBB) penetration. We show that compound 5, (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(7-(trifluoromethyl)4,5-dihydroimidazo[1,5-a]quinolin-3-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one [2379528-08-0], exhibits good brain exposure and potent 2-HG inhibition in a HT1080-derived mouse xenograft model, which makes it a potential preclin. candidate to treat IDH1-mutant brain tumors. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Formula: C8H15NO2

The Article related to glioblastoma antitumor pharmacokinetics isocitrate dehydrogenase 1 blood brain barrier, acute myeloid leukemia, blood-brain barrier, cancer therapy, glioblastoma, isocitrate dehydrogenase 1, small molecule inhibitors and other aspects.Formula: C8H15NO2

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On September 19, 2005, Jones, Simon; Selitsianos, Dimitrios published an article.Product Details of 168297-86-7 The title of the article was Stereochemical consequences of the use of chiral N-phosphoryl oxazolidinones in the attempted kinetic resolution of bromomagnesium alkoxides. And the article contained the following:

A number of chiral N-phosphoryl oxazolidinones, e.g. I (R = H, Ph, R1 = CH2Ph; R = Me, R1 = CHMe2), have been prepared and evaluated as asym. phosphoryl transfer agents with the magnesium alkoxide of 1-phenylethanol. The reaction proceeded with little stereoselection, which was shown to be a consequence of the reaction mechanism that occurs with inversion of configuration at phosphorus consistent with in-line attack opposite the leaving group. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Product Details of 168297-86-7

The Article related to failed kinetic resolution secondary alc chiral phosphoryloxazolidinone, chiral phosphoryloxazolidinone failed kinetic resolution secondary alkoxide, oxazolidinone phosphoryl failed kinetic resolution secondary alkoxide and other aspects.Product Details of 168297-86-7

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On November 3, 2004, Burke, Martin D.; Berger, Eric M.; Schreiber, Stuart L. published an article.Formula: C8H15NO2 The title of the article was A Synthesis Strategy Yielding Skeletally Diverse Small Molecules Combinatorially. And the article contained the following:

The efficient synthesis of small mols. having many mol. skeletons is an unsolved problem in diversity-oriented synthesis (DOS). We describe the development and application of a synthesis strategy that uses common reaction conditions to transform a collection of similar substrates into a collection of products having distinct mol. skeletons. The substrates have different appendages that pre-encode skeletal information, called σ-elements. This approach is analogous to the natural process of protein folding in which different primary sequences of amino acids are transformed into macromols. having distinct three-dimensional structures under common folding conditions. Like σ-elements, the amino acid sequences pre-encode structural information. An advantage of using folding processes to generate skeletal diversity in DOS is that skeletal information can be pre-encoded into substrates in a combinatorial fashion, similar to the way protein structural information is pre-encoded combinatorially in polypeptide sequences, thus making it possible to generate skeletal diversity in an efficient manner. This efficiency was realized in the context of a fully encoded, split-pool synthesis of ∼1260 compounds potentially representing all possible combinations of building block, stereochem., and skeletal diversity elements. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Formula: C8H15NO2

The Article related to oxazolidinone combinatorial library stereoselective preparation solid phase synthesis, split pool synthesis skeletal diversity combinatorial chem oxazolidinone preparation, combinatorial matrix mol skeleton furan derivatization and other aspects.Formula: C8H15NO2

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem

On February 9, 2017, Levell, Julian R.; Caferro, Thomas; Chenail, Gregg; Dix, Ina; Dooley, Julia; Firestone, Brant; Fortin, Pascal D.; Giraldes, John; Gould, Ty; Growney, Joseph D.; Jones, Michael D.; Kulathila, Raviraj; Lin, Fallon; Liu, Gang; Mueller, Arne; van der Plas, Simon; Slocum, Kelly; Smith, Troy; Terranova, Remi; Toure, B. Barry; Tyagi, Viraj; Wagner, Trixie; Xie, Xiaoling; Xu, Ming; Yang, Fan S.; Zhou, Liping X.; Pagliarini, Raymond; Cho, Young Shin published an article.Computed Properties of 168297-86-7 The title of the article was Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1. And the article contained the following:

High throughput screening and subsequent hit validation identified 4-isopropyl-3-(2-((1-phenylethyl)amino)pyrimidin-4-yl)oxazolidin-2-one as a potent inhibitor of IDH1R132H. Synthesis of the four sep. stereomers identified the (S,S)-diastereomer (IDH125, 1f) as the most potent isomer. This also showed reasonable cellular activity and excellent selectivity vs. IDH1wt. Initial SAR exploration identified the key tolerances and potential for optimization. X-ray crystallog. identified a functionally relevant allosteric binding site amenable to inhibitors which can penetrate the blood-brain barrier, and aided rational optimization. Potency improvement and modulation of the physico-chem. properties identified (S,S)-oxazolidinone IDH889 (5x) with good exposure and 2-HG inhibitory activity in a mutant IDH1 xenograft mouse model. The experimental process involved the reaction of (S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one(cas: 168297-86-7).Computed Properties of 168297-86-7

The Article related to pyrimidinyloxazolidinone preparation allosteric inhibitor isocitrate dehydrogenase idh1, 2-hg, 3-pyrimidin-4-yloxazolidin-2-one, mutant idh1 inhibitor, allosteric inhibition, chirality-defined potency, preclinical in vivo activity and other aspects.Computed Properties of 168297-86-7

Referemce:
Oxazolidine – Wikipedia,
Oxazolidine | C3H7NO – PubChem